Top Markets
#1 Nesa Nesa +873.71%
#2 MetaDAO MetaDAO +28.63%
#3 Prom Prom +16.34%
#4 Gigachad Gigachad +16.01%
#5 cat in a dogs world cat in a dogs world +12.72%
#6 dogwifhat dogwifhat +12.22%
#7 Tornado Cash Tornado Cash +10.73%
#8 Utya Utya +10.14%
#9 The Black Bull The Black Bull +9.62%
#10 TROLL TROLL +8.16%
Coin of the day
Nesa Nesa
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Celltrion, Inc. Celltrion, Inc.

Celltrion, Inc.

068270
Clasificación en acciones #830
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Precio por acción
$131.80
Capitalización bursátil
$30.23B
Cambio (1 día)
-1.75%
Cambio (1 año)
10.37%
País
KR
Comercio Celltrion, Inc. (068270)

Categoría

Healthcare
Historial de dividendos de Celltrion, Inc. (068270)
Celltrion, Inc. (símbolo bursátil: 068270) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Celltrion, Inc. (068270) desde 2026 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
Not enough data for the provided dates.
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
Not enough data for the provided dates.
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH